BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32808451)

  • 1. Cosmetovigilance in a tertiary care hospital: A prospective observational study.
    Jyrwa S; Sebastian J; Shastry V
    J Cosmet Dermatol; 2021 Mar; 20(3):804-811. PubMed ID: 32808451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis and Reporting of Adverse Drug Reactions of Cosmetics at a Tertiary Care Hospital.
    Paikray E; Bisoyi D; Rout A; Mishra V
    Cureus; 2024 Mar; 16(3):e56856. PubMed ID: 38659521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causality methods in cosmetovigilance: comparison of Colipa and PLM versus global introspection.
    Zweers PG; Gilmour NJ; Hepburn PA; Gerritsen RF; van Puijenbroek EP
    Regul Toxicol Pharmacol; 2012 Aug; 63(3):409-17. PubMed ID: 22609380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cosmetovigilance: definition, regulation and use "in practice".
    Vigan M; Castelain F
    Eur J Dermatol; 2014; 24(6):643-9. PubMed ID: 25672787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety in Cosmetics and Cosmetovigilance, Current Regulations in Türkiye.
    Altıokka İ; Üner M
    Turk J Pharm Sci; 2022 Oct; 19(5):610-617. PubMed ID: 36317955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Awareness level regarding adverse reactions caused by cosmetic products among female patients: A cross-sectional study.
    Nayak M; Ligade VS; Prabhu SS
    J Cosmet Dermatol; 2023 Sep; 22(9):2512-2519. PubMed ID: 36999455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An observational study on adverse reactions of cosmetics: The need of practice the Cosmetovigilance system.
    Lucca JM; Joseph R; Hussain Al Kubaish Z; Mohammad Al-Maskeen S; Ali Alokaili Z
    Saudi Pharm J; 2020 Jun; 28(6):746-753. PubMed ID: 32550807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notification of undesirable effects of cosmetics and toiletries.
    Sportiello L; Cammarota S; de Portu S; Sautebin L
    Pharmacol Res; 2009 Feb; 59(2):101-6. PubMed ID: 19028583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding the adverse effects of cosmetics: a pilot project in cosmetovigilance.
    Sautebin L
    Drug Saf; 2008; 31(5):433-6. PubMed ID: 18422386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cosmetics Use-Related Adverse Events and Determinants Among Jigjiga Town Residents, Eastern Ethiopia.
    Bilal AI; Tilahun Z; Osman ED; Mulugeta A; Shekabdulahi M; Berhe DF
    Dermatol Ther (Heidelb); 2017 Mar; 7(1):143-153. PubMed ID: 27882506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cosmetovigilance survey in Europe.
    Sautebin L
    Pharmacol Res; 2007 May; 55(5):455-60. PubMed ID: 17368906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cosmetovigilance: a French pharmacovigilance system for cosmetics developed by the French health products safety agency. A proposal for the future].
    Tissier MH; Lepagnol F
    Therapie; 2002; 57(3):273-82. PubMed ID: 12422542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cosmetovigilance survey: are cosmetics considered safe by consumers?
    Di Giovanni C; Arcoraci V; Gambardella L; Sautebin L
    Pharmacol Res; 2006 Jan; 53(1):16-21. PubMed ID: 16183300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of undesirable events in cosmetic market surveillance: background, description and use of a causality assessment method in cosmetovigilance.
    Bons B; Audebert F; Bitaudeau C; Cachin N; Colson L; Farr C; Fix LA; Gilmour N; Gorni R; Griffiths M; Harris B; Holle V; Kirk S; Meredith E; Pari C; Poinsot P; Renner G;
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):349-53. PubMed ID: 20619309
    [No Abstract]   [Full Text] [Related]  

  • 15. Surveillance of dermo-cosmetic products: a global cosmetovigilance system to optimise product development and consumer safety.
    Ribet V; Albinet Claudin L; Brinio E; Berthier A; Millet V; Halbeher C; Sauvaire L; Laborderie M; Lafosse S; Olivan A; Giordano Labadie F; Ferret PJ
    Eur J Dermatol; 2021 Aug; ():. PubMed ID: 34463281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cosmetovigilance: A review of the current literature.
    Toklu HZ; Antigua A; Lewis V; Reynolds M; Jones J
    J Family Med Prim Care; 2019 May; 8(5):1540-1545. PubMed ID: 31198710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Questionnaire-Based Study of 392 Women in Abbottabad, Pakistan, to Evaluate the Types of Cosmetic Products Purchased Between December 2018 and March 2019 and Their Associated Adverse Events.
    Nisar F; Ali A; Shahid H; Iqbal MM; Khan H; Khan Q; Iqbal A; Samreen S; Syed W; Al-Rawi MBA
    Med Sci Monit Basic Res; 2024 Mar; 30():e943048. PubMed ID: 38549239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Observational Study on Cosmetics Use-related Adverse Effects: Cosmetovigilance Need of the Day.
    Mehta G; Tyagi DR; Sachdeva M; Tripathi R; Tyagi H
    Drug Res (Stuttg); 2024 Apr; 74(4):164-170. PubMed ID: 38467158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cosmetovigilance: the 'beautiful' risk.
    Moretti U; Velo G
    Drug Saf; 2008; 31(5):437-9. PubMed ID: 18422387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cross-sectional Survey-based Study of Knowledge, Attitude, and Practice Towards Uses of Cosmetics and Cosmetovigilance in India.
    Siddiqui A; Ali N; Pandey A; Ali MD; Haider N; Khan MZ; Iqbal Z; Mirza MA; Alharthi S; Ansari MS; Mustafa G; Ahmad S
    J Pharm Bioallied Sci; 2024; 16(1):31-37. PubMed ID: 38694964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.